Home

TLDR Biotech

The top stories in biotech & pharma, straight to your inbox in only one email.
Trusted by 2700+ biotech and pharma professionals.

Comprehensive daily coverage of the biotech and pharma industry, straight to your inbox.

TLDR Biotech

The Latest Biotech & Pharma Updates

Biotech & Pharma Updates | April 1 - 5, 2026

Apr 6, 2026

•

9 min read

Biotech & Pharma Updates | April 1 - 5, 2026

🧬 Anthropic acquires stealth biotech Coefficient Bio for $400M to expand AI-driven drug research and development capabilities, Novo Nordisk claims indirect data show oral Wegovy outperforms Eli Lilly's Foundayo in obesity treatment comparison, Transgene licenses NEC Bio's AI neoantigen prediction platform for TG4050 - €5M ($5.77M) plus milestones

Anis Fahandej-Sadi

Biotech & Pharma Updates | March 31 - April 1, 2026

Apr 2, 2026

•

8 min read

Biotech & Pharma Updates | March 31 - April 1, 2026

🧬 Eli Lilly's Foundayo (orforglipron) wins FDA approval for obesity treatment following Ph3 success, Korsana Biosciences to go public via Cyclerion Therapeutics reverse merger with $380M funding, Syneron Bio raises $150M Series B, advancing macrocyclic peptide drug discovery platform

Anis Fahandej-Sadi

Biotech & Pharma Updates | March 30 - 31, 2026

Apr 1, 2026

•

9 min read

Biotech & Pharma Updates | March 30 - 31, 2026

🧬 Eli Lilly to acquire Centessa Pharmaceuticals for $6.3B to enter sleep disorder market - ultimately challenging Takeda, Ambrosia Biosciences raises $100M Series B - developing oral weight-loss medications, BMS + Faro partner on multi-year AI clinical trial protocol improvement agreement

Anis Fahandej-Sadi

Biotech & Pharma Updates | March 29 - 30, 2026

Mar 31, 2026

•

8 min read

Biotech & Pharma Updates | March 29 - 30, 2026

🧬 Blackstone closes $6.3B fund for life sciences investing and partnerships, Royalty Pharma's $500M investment to Johnson & Johnson to co-fund autoimmune antibody JNJ-4804, FDA approves Biogen's high-dose Spinraza ASO targeting SMN2 for SMA

Anis Fahandej-Sadi

Biotech & Pharma Updates | March 26 - 29, 2026

Mar 30, 2026

•

8 min read

Biotech & Pharma Updates | March 26 - 29, 2026

🧬 Eli Lilly + Insilico Medicine expand AI drug discovery collaboration - $115M upfront + $2.75B total value, AstraZeneca's tozorakimab hits Ph3 endpoints for chronic obstructive pulmonary disease targeting IL-33 pathway, Terrestrial Bio raises $50M Series C - developing microarray patch therapeutic delivery platform

Anis Fahandej-Sadi

Biotech & Pharma Updates | March 25 - 26, 2026

Mar 27, 2026

•

7 min read

Biotech & Pharma Updates | March 25 - 26, 2026

🧬 Pinnacle Medicines raises $89M Series B - advancing oral peptide therapeutics platform, Neion Bio emerges from stealth with egg-based biosimilar partnership to develop three monoclonal antibodies, Insilico Medicine + Tenacia Biotechnology expand AI-driven CNS collaboration with $94.75M deal value

Anis Fahandej-Sadi

Biotech & Pharma Updates | March 24 - 25, 2026

Mar 26, 2026

•

9 min read

Biotech & Pharma Updates | March 24 - 25, 2026

🧬 Merck & Co. to acquire Terns Pharmaceuticals for $6.7B - targeting TERN-701 leukemia drug ahead of Keytruda cliff, Biogen + Alteogen partner on subcutaneous delivery tech - $20M upfront + $559M potential milestones, Denali Therapeutics' Avlayah (tividenofusp alfa-eknm) wins FDA accelerated approval for Hunter syndrome neurologic manifestations

Anis Fahandej-Sadi

Biotech & Pharma Updates | March 23 - 24, 2026

Mar 25, 2026

•

8 min read

Biotech & Pharma Updates | March 23 - 24, 2026

🧬 UCB to build $2B biologics manufacturing facility near Atlanta headquarters, creating 330 jobs, Ocugen advances OCU410 gene therapy targeting RORA to Ph3 for geographic atrophy following positive Ph2 results, Merck & Co. + Quotient Therapeutics partner on IBD drug discovery - $20M upfront + $2.2B milestones

Anis Fahandej-Sadi

Biotech & Pharma Updates | March 22 - 23

Mar 24, 2026

•

8 min read

Biotech & Pharma Updates | March 22 - 23

🧬 Novartis commits $480M to expand manufacturing in Beijing and R&D operations in Shanghai, Oryon Cell Therapies raises $42M Series A - Parkinson's cell therapy replacing dopaminergic neurons, Sanofi + Kali Therapeutics partner on autoimmune tri-specific antibody KT501 - $180M upfront + $1.05B milestones

Anis Fahandej-Sadi

...

The Latest Biotech & Pharma Updates

Biotech & Pharma Updates | April 1 - 5, 2026

Biotech & Pharma Updates | March 31 - April 1, 2026

Biotech & Pharma Updates | March 30 - 31, 2026

Biotech & Pharma Updates | March 29 - 30, 2026

Biotech & Pharma Updates | March 26 - 29, 2026

Biotech & Pharma Updates | March 25 - 26, 2026

Biotech & Pharma Updates | March 24 - 25, 2026

Biotech & Pharma Updates | March 23 - 24, 2026

Biotech & Pharma Updates | March 22 - 23

TLDR Biotech

FAQ

Media Partners